¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"two hit hypothesis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • apical two chamber view
    ½É÷2¹æµµ
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • hypothesis
    °¡¼³
  • lattice hypothesis
    °ÝÀÚ°¡¼³
  • null hypothesis
    ¿µ°¡¼³, ±Í¹«°¡¼³
  • unitarian hypothesis
    Ç×üµ¿Àϰ¡¼³
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • null hypothesis
    ±Í¹«°¡¼³, ¿µ°¡¼³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • two hit hypothesis
    ÀÌŸ°¡¼³
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁ߸ðµ¨
  • apical two chamber view
    ½ÉÀ峡µÎ¹æ´Ü¸éµµ
  • two-way catheter
    µÎ±æÄ«Å×ÅÍ
  • two point discrimination
    µÎÁ¡½Äº°
  • two-point gait
    µÎÁ¡º¸Çà
  • two-slide method
    ÀÌÁß½½¶óÀ̵å¹ý
  • standard double two step test
    Ç¥ÁØÀÌÁßÀ̴ܰè°Ë»ç
  • two stage sampling
    ÀÌ´ÜÇ¥º»ÃßÃâ¹ý
  • two point threshold
    µÎÁ¡½Äº°¹®Åΰª, µÎÁ¡½Äº°¿ªÄ¡
  • two-tail test
    ¾çÃø°ËÁ¤
  • blending hypothesis
    À¶ÇÕÀ¯Àü¼³
  • central plasticity hypothesis
    ÁßÃßÀ¯¿¬¼º°¡¼³
  • countercurrent hypothesis
    ¿ª·ù°¡¼³
  • drift hypothesis
    À̵¿°¡¼³
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • HIT= hemagglutination inhibition test
    Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • grazing hit
    Âû°úŸ°Ý
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • Glucostatic hypothesis, of appetite regulation
    Ç×´ç±â¼³(ù÷ÓØÐñæò), ½Ä¿åÁ¶Àý(ãÝé¯ðàï½)
  • Lyon s hypothesis
    ¶óÀ̿°¡¼³.
  • Starling s hypothesis
    ½ºÅ¸¾Ë¸µ°¡¼³.
  • hypothesis, lattice
    °ÝÀÚ¼³
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • two hit hypothesis
    ÀÌŸ°¡¼³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • grazing hit
    Âû°úŸ°Ý
  • hemagglutination inhibition test =HIT
    (Àû)Ç÷±¸ÀÀÁý¾ïÁ¦½ÃÇè.
  • multitarget single hit model
    ´ÙÇ¥Àû´ÜÀÏÀûÁß
  • single target multi-hit model
    ´ÜÀÏÇ¥Àû´Ù¹ßÀûÁß ¸ðµ¨
  • atherosclerosis,monoclonal hypothesis
    ´ÜÀÏŬ·Ð¼º°¡¼³(Ó¤ìé¡­Ê£àã)
  • atherosclerosis,reaction to injury hypothesis
    ¼Õ»ó¿¡ ´ëÇÑ ¹ÝÀÀ±âÀü
  • atomic hypothesis
    ¿øÀÚ°¡¼³(ê«í­Ê£æò).
  • blending hypothesis
    À¶ÇÕÀ¯Àü¼³(¡­ë¶îîæò).
  • countercurrent hypothesis
    ¿ª·ù°¡¼³ (¡­Ê£æò).
  • cyclol hypothesis
    »çÀÌŬ·Ñ ´ÜÀ§°¡¼³(¡­Ó¤êÈÊ£æò).
  • dopamine hypothesis
    µµÆÄ¹Î °¡¼³
  • drift hypothesis
    À̵¿°¡¼³
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
  • emphysema,protease-antiprotease hypothesis
    ´Ü¹é-Ç״ܹéºÐÇØÈ¿¼Ò °¡¼³
  • estrogen window hypothesis
    ¿¡½ºÆ®·ÎÁ¨ ±¸°£°¡¼³
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • two-messenger hypothesis
    ÀÌ(ì£)Àü·É(îîÖµ)¼³(àã)
  • hit theory
    °¡°Ý ÀÌ·Ð(ʥ̪×âÖå)
  • lethal hit
    Ä¡»ç°¡°Ý(öÈÞÝʥ̪)
  • one-hit theory
    Àϰݼ³(àã)
  • two-carbon fragment
    ÀÌź¼Ò(ì£÷©áÈ) Á¶°¢
  • two-dimensional chromatography
    ÀÌÂ÷¿ø(ì£ó­êª)Å©·Î¸¶Åä±×·¡ÇÇ
  • two-dimensional electrophoresis
    ÀÌÂ÷¿ø Àü±â¿µµ¿(ì£ó­êªï³Ñ¨ç¶ÔÑ)
  • two-factor cross
    ÀÌÀÎÀÚ ±³Â÷(ì£ì×í­Îßó©)
  • two-five A
    ¿À(çé)A ÀÌÁ¶(ì£ðÚ)
  • two-genes-one-polypeptide chain
    ÀÌÀ¯ÀüÀÚ(ì£ë¶îîí­)- ÀÏ(ìé)Æú¸®ÆéŸÀÌµå »ç½½
  • two out of three method
    »ïÁß ÅÃÀ̹ý(ß²ñé÷Éì£Ûö)
  • two-point cross
    ÀÌÁ¡±³Â÷(ì£ïÇÎßó©)
  • two-state model
    ¾ç»ó(å»ßÒ)¸ðµ¨
  • acetate hypothesis
    ¾Æ¼¼Æ®»ê(ß«) ¼³(àã)
  • adapter hypothesis
    ¾Æ´äÅͼ³(àã)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • two chambered right ventricle
    ¿ì½É½Ç¾çºÐÁõ
  • two dimensional Fourier transform
    ÀÌÂ÷¿øÇ»¸®¾îº¯È¯
  • two filamensional echocardiography
    À̸鼺ÃÊÀ½ÆÄ¼ú
  • two lumen catheter
    2°­ Ä«Å×ÅÍ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
HIT hemagglutination inhibition test; heparin-induced thrombocytopenia; histamine inhalation test; hyper...
H0 null hypothesis
H1 alternative hypothesis
LNH large number hypothesis
TRH tension-reducing hypothesis; thyrotropin-releasing hormone
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
(3)H hypothesis that
HIT Hemagglutination inhibition test
HIT Heparin induced thrombocytopenia
HIT II Heparin-induced thrombocytopenia type II
HIT Holtzman Inkblot Technique
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • altered-self hypothesis
    º¯È­ÇÑ ÀÚ±â Ç׿ø °¡¼³
    T-B Çùµ¿ÀÛ¿ëÀ̳ª Killer T ¼¼Æ÷ÀÇ Ç¥Àû¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ À־ ¸²ÇÁ±¸´Â ¹ÝÀÀÇÏ´Â »ó´ëÀÇ ±¸Á¶·Î¼­ ºñÀÚ±âÀÎ Ç׿ø°ú ÀÚ±âÀÎ MHCÀÇ ¾çÂÊÀ» ÀνÄÇϰí ÀÖ´Ù. ÀÌ °æ¿ì »ý°¢ÇÏ´Â ¹æ½Ä¿¡ µÎ °³ÀÇ ¹æ½ÄÀÌ ÀÖÀ¸¸ç ºñÀÚ±â¿Í ÀڱⰡ ÇϳªÀÇ °ÍÀ¸·Î¼­ ÇÑ Á¾·ùÀÇ ¼ö¿ëü¿¡ ÀÇÇÏ¿© ÀÎ½ÄµÈ´Ù°í »ý°¢ÇÏ´Â °ÍÀÌ º¯È­ÇÑ ÀÚ°¡ Ç׿ø °¡¼³ÀÇ »ý°¢ ¹æ½ÄÀÌ´Ù.
  • convergence-projection hypothesis
    ÆøÁÖ Åõ»ç °¡¼³
  • dual recognition hypothesis
    2Áß Àνļ³
    ¸é¿ª ¼¼Æ÷ »çÀÌÀÇ »óÈ£ ÀÛ¿ë¿¡ À־ÀÇ T ¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ °üÇÑ °¡¼³ÀÇ Çϳª. T ¼¼Æ÷¿¡´Â ÀÚ±âÀÇ MHC ºÐÀÚ¸¦ ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü¿Í ´Ù¸¥ °ÍÀ» ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü°¡ °¢°¢ µ¶¸³ÇÏ¿© Á¸ÀçÇÑ´Ù°í ÇÏ´Â »ý°¢.
  • hypothesis
    °¡¼³
    ¸î °¡ÁöÀÇ Çö»óÀ» ¼³¸íÇÒ ¼ö ÀÖÀ¸¸ç Ãß·ÐÀ̳ª ½ÇÇèÀ» ±âÃÊ·Î ÇÏ¿© °¡Á¤µÈ ÃßÃø.
  • Starling's hypothesis
    ½ºÅ»¸µÀÇ °¡¼³
  • unitarian hypothesis
    Ç×ü µ¿Àϼ³
  • anterior two thirds
    Àü¹æ 2/3
  • apical two chamber view
    ½É÷ 2¹æ ´Ü¸éµµ
  • simultaneous two-jaw surgery
    ¾ç¾Ç µ¿½Ã À̵¿ ¼ö¼ú
  • two dimensional Fourier transform
    ÀÌÂ÷¿ø Ç»¸®¾î º¯È¯
  • two lumen catheter
    2°­ Ä«Å×ÅÍ
  • two piece crown
    ºÀ¼º ±Ý°ü
  • two-phase color reaction
    µÎ °¡Áö »ö±ò ¹ÝÀÀ
  • two-point discrimination testing
    µÎ Á¡ ½Äº°´É °Ë»ç
  • two-stage prothrombin test
    ÀÌ ´Ü°è ÇÁ·ÎÆ®·Òºó ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
adaptor hypothesis A hypothesis, proposed by F.H.C. Crick, that an adaptor molecule must be present between the information-containing DNA and the protein being synthesised.
(05 Mar 2000)
altered self hypothesis The hypothesis that the T-cell receptor in MHC mediated phenomena recognises a syngeneic MHC Class I or Class II molecule after modification by a virus or certain chemicals.
See: MHC restriction.
(18 Nov 1997)
alternative hypothesis In Neyman-Pearson testing of a hypothesis, the hypothesis or family of hypotheses about the numerical value of a parameter if and only if the null hypothesis is rejected as untenable.
(05 Mar 2000)
autocrine hypothesis That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation.
(05 Mar 2000)
Avogadro's hypothesis <physics> The hypothesis that equal volumes of two different gases at the same temperature and pressure contain the same number of molecules.
(02 Jan 1998)
Bayesian hypothesis An array of surmised values of a parameter to be severally explored in the light of a current set of data, with logical symmetry being preserved among all. The merits of each hypothesis entertained are based on quantity, the prior probability. The probability of the data conditional on the hypothesis is computed as the conditional probability for each; the product of the two for each hypothesis is the joint probability, and the ratio of each joint probability to the sum of all the joint probabilities is the posterior probability for that hypothesis. Unlike the Neyman-Pearson test of hypotheses, the answer is a statement about the hypothesis, not about the sample conditional on the hypothesis. No hypothesis is preferred or prevails by default. The procedure may be applied recursively any number of times, as the data becomes available.
(05 Mar 2000)
bufadienolides (two double bonds) Bufatrienolides (three double bonds), etc; they have varying numbers of hydroxyl groups at positions 3, 5, 14, and 16, and these may be further substituted. For structure, see steroids.
(05 Mar 2000)
Makeham's hypothesis A development of Gompertz' hypothesis as to the force of mortality following some mathematical law. Makeham assumed that death was the consequence of two generally coexisting causes: 1) chance; 2) a deterioration or increased inability to withstand destruction. The first of these is constant, the second is an increasing geometrical progression.
(05 Mar 2000)
gate-control hypothesis A theory to explain the mechanism of pain; small fibre afferent stimuli, particularly pain, entering the substantia gelatinosa can be modulated by large fibre afferent stimuli and descending spinal pathways so that their transmission to ascending spinal pathways is blocked (gated).
Synonym: gate-control hypothesis.
(05 Mar 2000)
gel diffusion precipitin tests in two dimensions Precipitin test's made in a layer of agar that permits radial diffusion, in both of the horizontal dimensions, of one or both reactants. Double (gel) diffusion in two dimensions (Ouchterlony test, technique, or method) incorporates antigen and antibody solutions placed in separate wells in a sheet of plain agar, permitting radial diffusion of both reactants; this method is widely used to determine antigenic relationships; the bands of precipitate that form where the reactants meet in optimal concentration are of three patterns, referred to as reaction of identity, reaction of partial identity (cross-reaction), and reaction of nonidentity.
(05 Mar 2000)
Master's two-step exercise test An early and long-used exercise challenge to identify ischemic heart disease using a pair of nine inch steps with a platform on top, the number of trips by the patient arbitrarily chosen and related to age and body weight.
See: two-step exercise test.
Synonym: Master's two-step exercise test.
(05 Mar 2000)
Gompertz' hypothesis A theory that the force of mortality increases in geometrical progression, being based on the assumption that the average exhaustion of a person's power to avoid death is such that at the end of equal infinitely small intervals of time he loses equal proportions of the power to oppose destruction which he had at the commencement of each of these intervals.
(05 Mar 2000)
chemiosmotic hypothesis <biochemistry, cell biology> A theoretical mechanism (proposed by Mitchell) to explain energy transduction in the mitochondrion. As a general mechanism it is the coupling of one enzyme catalysed reaction to another using the transmembrane flow of an intermediate species. For example Cytochrome oxidase pumps protons across the mitochondrial inner membrane and ATP synthesis is driven by re entry of protons through the ATP synthesising protein complex. The alternative model is production of a chemical intermediate species, but no compound capable of coupling these reactions has ever been identified.
(18 Nov 1997)
Michaelis-Menten hypothesis <chemistry> That a complex is formed between an enzyme and its substrate (the O'Sullivan-Tompson hypothesis), which complex then decomposes to yield free enzyme and the reaction products (Brown hypothesis), the latter rate determining the overall rate of substrate-product conversion.
See: Michaelis-Menten constant, Michaelis-Menten equation.
(05 Mar 2000)
mnaemic hypothesis The theory that stimuli or irritants leave definite traces (engrams) on the protoplasm of the animal or plant, and when these stimuli are regularly repeated they induce a habit which persists after the stimuli cease; assuming that the germ cells share with the nerve cells in the possession of engrams, acquired habits may thus be transmitted to the descendants.
Synonym: mnaemic theory, mnemism, Semon-Hering theory.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • efficient market hypothesis
    (Áõ±Ç)È¿À²Àû ½ÃÀå °¡¼³(»õ·Î¿î Á¤º¸ÀÇ ÁÖ°¡¿¡ÀÇ ¹ÝÀÀÀº µ¿½ÃÀûÀ̶õ °¡¼³)
  • hypothesis
    °¡¼³;°¡Á¤
  • nebular hypothesis(theory)
    (õ)(žç°èÀÇ)¼º¿î¼³
  • two
    µÑ
  • two-line
    ¹èÇüÀÇ
  • two-lined
    ¹èÇüÀÇ
  • two-tone
    ÅõÅæ Ä®·¯ÀÇ
  • two-toned
    ÅõÅæ Ä®·¯ÀÇ
  • number two
    Á¦ 2ÀÎÀÚ º¸Á¿ª;¶Ë;´ëº¯
  • two
    2(ÀÇ);µÎ °³(»ç¶÷)(ÀÇ);a day or ~ ÇÏ·çÀÌÆ²;by ~s and threes µå¹®µå¹®;»ï»ï¿À¿À;in ~ µÎ µ¿°­À¸·Î;in ~ ~s °ð.¼ø½Ä°£¿¡;put ~ and ~ together ÀÌ°Í Àú°Í Á¾ÇÕÇÏ¿© »ý°¢ÇÏ´Ù;°á·ÐÀ» ³»´Ù;~ and ~ or ~ by ~ µÑ¾¿
  • hit
    Ä¡´Ù
  • hit on
    ¿ì¿¬È÷ »ý°¢³ª´Ù
  • base hit
    ¾ÈŸ
  • extrabase hit
    ÀåŸ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á